Novartis Closes MorphoSys Sites and Cuts 330 Jobs Amid Acquisition Challenges and Strategic Realignment

In a strategic realignment following the acquisition of MorphoSys, Novartis is closing facilities in Munich and Boston, leading to the elimination of approximately 330 jobs[1][2]. This move is part of Novartis's broader integration plan to incorporate MorphoSys's activities into its own operations while managing research and development priorities[3]. The acquisition, which took place earlier in the year for approximately $2.9 billion, highlights Novartis's interest in MorphoSys’s late-stage oncology candidate pelabresib, although its advancement has faced challenges due to safety concerns that have delayed regulatory approval timelines[2][3]. Despite these hurdles, Novartis remains focused on the development of pelabresib, emphasizing its strategic importance while collaborating with MorphoSys's teams to facilitate a smoother integration and future success[1][3].